AIDS critic seeks vote on Gilead's 'predatory' pricing
This article was originally published in Scrip
With its lobbying efforts on the price of Gilead Sciences' new four-drug HIV combo Stribild apparently having a limited effect, frequent Gilead Sciences critic the AIDS Healthcare Foundation (AHF) is now sponsoring a local ballot initiative in San Francisco that could force local, state and federal governments to negotiate lower prices.
You may also be interested in...
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?